Alessandra Marsella

Alessandra Marsella

Auto-generated profile, based on publicly available information

Alessandra Marsella

Istituto Italiano di Tecnologia (IIT), Center for Bio-Molecular Nanotechnologies, Via Barsanti, 73010, Arnesano, Lecce, Italy and Department of Engineering for Innovation, University of Salento, Via per Monteroni, 73100, Lecce, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2020 in Nanoscale
Verified
Journal Article
Closed access
PDF file
GUGayatri Udayan
Gayatri Udayan
AMAlessandra Marsella
Alessandra Marsella
PVPaola Valentini
Paola Valentini
Targeted therapies for cutaneous melanoma, such as those based on specific BRAF inhibitors, have improved the treatment and enhanced the survival rate of patients who harbor the V600E point mutation in the BRAF gene. However, tissue biopsies to characterize BRAF mutation status are prone to sampling bias, due to the intrinsic heterogeneity of a tumor mass. In contrast, blood biopsies, which analyze circulating tumor DNA (ctDNA), offer the most complete and sensitive characterization of the mutation status of a tumor, provide early and more accurate diagnosis, but they require instrumental and costly molecular tests. Therefore, the development of low-cost but highly sensitive tests for the non-invasive identification of BRAFV600E mutation in ctDNA would be of great clinical utility as a routine screening for the early identification of responsive patients and the follow-up of targeted therapy's response. The present work developed a naked-eye, inexpensive, yet very specific colorimetric assay, whose sensitivity is suitable for the detection of BRAFV600E rare mutation in ctDNA. Such test potentially may detect at an early stage the mutation in the tumor mass, when the first mutated cells appear in the blood, by using minimal instrumentation and thus enabling its widespread implementation in the clinics, even in local, minimally equipped laboratories. Indeed, the test detects 0.5% of BRAFV600E in an excess of BRAFWT DNA, which matches the sensitivity of some commercial instrumental assays. Such sensitivity is thus clinically relevant for diagnostic purposes, allowing the early identification of drug-sensitive patients.

28 April 2016 in Nanoscale
Verified
Journal Article
Open access
PDF file
PVPaola Valentini
Paola Valentini
AMAlessandra Marsella
Alessandra Marsella
PTPaolo Tarantino
Paolo Tarantino
SMSalvatore Mauro
Salvatore Mauro
SBSilvia Baglietto
Silvia Baglietto
Pier Paolo PompaPier Paolo Pompa
Pier Paolo Pompa
We report a low-cost test, based on gold nanoparticles, for the colorimetric (naked-eye) fingerprinting of a panel of single nucleotide polymorphisms (SNPs), relevant for the personalized therapy of psoriasis. Such pharmacogenomic tests are not routinely performed on psoriasis patients, due to the high cost of standard technologies. We demonstrated high sensitivity and specificity of our colorimetric test by validating it on a cohort of 30 patients, through a double-blind comparison with two state-of-the-art instrumental techniques, namely reverse dot blotting and sequencing, finding 100% agreement. This test offers high parallelization capabilities and can be easily generalized to other SNPs of clinical relevance, finding broad utility in diagnostics and pharmacogenomics.

27 April 2016
Verified
Conference Paper
Closed access
PDF file
AMAlessandra Marsella
Alessandra Marsella
PVPaola Valentini
Paola Valentini
PTPaolo Tarantino
Paolo Tarantino
MCMaurizio Congedo
Maurizio Congedo
PPPier Paolo Pompa
Pier Paolo Pompa